Mineralys Therapeutics Earnings Reports

Mineralys Therapeutics reported a net loss of $42.2 million for the first quarter of 2025, an increase from $31.5 million in the same period last year, primarily due to increased research and development and general and administrative expenses. The company ended the quarter with a strong cash position of $343.0 million following a public equity financing.

Mineralys Therapeutics reported a net loss of $24.4 million for the fourth quarter of 2023, compared to a net loss of $9.1 million for the same period in 2022. Cash, cash equivalents and investments were $239.0 million as of December 31, 2023. The company believes that its current cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations, into 2026.

Mineralys Therapeutics reported its Q4 and full year 2022 financial results, highlighting the upcoming pivotal clinical program for lorundrostat and the completion of its IPO in February 2023. The company is focused on developing treatments for diseases driven by elevated aldosterone.